Compare CRT & DRIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRT | DRIO |
|---|---|---|
| Founded | 1991 | 2011 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.9M | 52.8M |
| IPO Year | N/A | 2013 |
| Metric | CRT | DRIO |
|---|---|---|
| Price | $11.31 | $6.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 19.1K | ★ 19.5K |
| Earning Date | 04-14-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.29% | N/A |
| EPS Growth | N/A | ★ 1559.02 |
| EPS | N/A | ★ 1.75 |
| Revenue | N/A | ★ $7,394,000.00 |
| Revenue This Year | N/A | $20.27 |
| Revenue Next Year | N/A | $47.58 |
| P/E Ratio | $11.55 | ★ $4.02 |
| Revenue Growth | N/A | ★ 43.02 |
| 52 Week Low | $7.07 | $5.84 |
| 52 Week High | $11.43 | $17.74 |
| Indicator | CRT | DRIO |
|---|---|---|
| Relative Strength Index (RSI) | 75.76 | 45.97 |
| Support Level | $10.18 | $6.18 |
| Resistance Level | N/A | $8.10 |
| Average True Range (ATR) | 0.27 | 0.60 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 85.00 | 29.19 |
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.